ACTRN12606000024549尚未招募2 期
Randomised placebo controlled trial on the safety and efficacy of Biolane in osteoarthritis of the knees and/or hips
Healtheries of New Zealand Ltd0 个研究点目标入组 100 人开始时间: 2006年1月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Total WOMAC score of >30 at baseline-x-ray and clinical evidence of osteoarthritis of the knees and/or hips.
排除标准
- •Gout, rheumatoid arthritis or other inflammatory joint condition-Allergy to seafood or gelatine-Use of monoamine oxidase inhibitors-Use of corticosteroids within 4 weeks prior to baseline and throughout the study-Use of aspirin or anti-inflammatory agents 3 weeks prior to baseline and for the duration of the study-Use of complementary anti-arthritic medicines 6 weeks prior to baseline and for the duration of the study-Liver function tests greater then 3 times the upper limit of normal at baseline.
研究者
相似试验
已完成
不适用
Randomised placebo controlled trial on the safety and efficacy of a topical treatment for bilaternal chronic plaque psoriasis in adultsISRCTN74459383H BioJuven Pty Ltd (Australia)29
已完成
2 期
Randomised placebo controlled trial on the safety and efficacy of BSP-201 in osteoarthritisOsteoarthritis of the knees and/or hipsMusculoskeletal - OsteoarthritisACTRN12606000162516BSP Pharma A/S (this is the full name of company)128
已完成
2 期
Randomised placebo controlled study on the safety and efficacy of a herbal tonic for cessation of smoking - five week pilot studySmokingPublic Health - Health promotion/educationACTRN12605000296639CigArrest Pty ltd60
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of ALD403MigraineACTRN12614000681651Alder Biopharmaceuticals60
进行中（未招募）
不适用
A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's DiseaseIdiopathic Parkinson's disease (paralysis agitans)MedDRA version: 9.1Level: LLTClassification code 10034010Term: ParkinsonismEUCTR2009-010193-38-LVIMPAX Laboratories, Inc.350